Introduction {#s1}
============

SOX2 is a crucial transcription factor involved in the specification and maintenance of multiple stem cell populations in mammals. Pituitary stem cells express SOX2 and contribute to the generation of new endocrine cells during embryonic development and throughout postnatal life ([@bib4]; [@bib44]). The pituitary gland is composed of three parts, the anterior, intermediate and posterior lobes (AL, IL and PL, respectively). The AL and IL contain hormone-secreting cells, which are derived from an evagination of the oral ectoderm expressing SOX2, termed Rathke's pouch (RP). SOX2+ cells, both in the embryonic and adult pituitary, can differentiate into three endocrine cell lineages, which are marked by transcription factors PIT1 (POU1F1) ([@bib26]), TPIT (TBX19) ([@bib43]) and SF1 (NR5A1) ([@bib19]), and differentiate into hormone-secreting cells (somatotrophs, lactotrophs, thyrotrophs, corticotrophs, melanotrophs and gonadotrophs, which express growth hormone, prolactin, thyrotropin, adrenocorticotropin, melanotropin and gonadotropin, respectively). SOX2+ PSCs are highly proliferative during the first 2--3 weeks of life, in concordance with major organ growth, after which they reach a steady low proliferative capacity that contributes to maintain normal homeostasis and physiological adaptation of the pituitary gland ([@bib24]; [@bib37]).

Contrary to other organs, where somatic stem cells are shown to be able to become transformed into cancer stem cells, the roles of SOX2+ PSCs in tumourigenesis remain poorly understood, possibly due to the patchy knowledge of the pathways regulating SOX2+ PSC fate and proliferation. Pituitary tumours are common in the population, representing 10--15% of all intracranial neoplasms ([@bib7]; [@bib11]). Adenomas are the most common adult pituitary tumours, classified into functioning, when they secrete one or more of the pituitary hormones, or non-functioning if they do not secrete hormones. In children, adamantinomatous craniopharyngioma (ACP) is the most common pituitary tumour. Targeting oncogenic beta-catenin in SOX2+ PSCs in the mouse generates clusters of senescent SOX2+ cells that induce tumours resembling ACP in a paracrine manner, that is the tumours do not derive from the targeted SOX2+ PSCs ([@bib4]; [@bib14]). Up to 15% of adenomas and 50% of ACP display aggressive behaviour with invasion of nearby structures including the hypothalamus and visual tracts, associated with significant morbidity and mortality ([@bib21]). Pituitary carcinomas exhibiting metastasis are rare but can develop from benign tumours ([@bib54]; [@bib42]; [@bib17]). Whether SOX2+ cells can cell autonomously contribute to pituitary neoplasia has not been hitherto demonstrated.

The Hippo pathway controls stem cell proliferation and tumourigenesis in several organs such as in the liver ([@bib59]; [@bib30]), intestines ([@bib60]) and lung ([@bib27]; [@bib36]). In the core phosphorylation cascade, STK3/4 kinases phosphorylate and activate LATS1/2 serine/threonine-protein kinases, which in turn phosphorylate co-activators Yes-associated protein (YAP1, a.k.a. YAP) and WW domain-containing transcription regulator protein 1 (WWTR1, a.k.a. TAZ) that are subsequently inactivated through degradation and cytoplasmic retention ([@bib32]). Active YAP/TAZ associate with TEAD transcription factors, promoting the transcription of target genes such as *Cyr61* and *Ctgf* ([@bib58]; [@bib57]; [@bib61]). YAP/TAZ have been shown to promote proliferation and the stem cell state in several organs, and can also lead to transformation and tumour initiation when overexpressed ([@bib8]; [@bib48]; [@bib12]). The involvement of YAP/TAZ in the function of tissue-specific SOX2+ stem cells during development and homeostasis has not been shown. We previously reported strong nuclear localisation of YAP and TAZ exclusively in SOX2+ stem cells of developing Rathke\'s pouch and the postnatal anterior pituitary of mice and humans, and enhanced expression in human pituitary tumours composed of uncommitted cells, including ACPs and null-cell adenomas ([@bib28]; [@bib55]), which do not express any of the lineage transcription factors PIT1, TPIT or SF1. In these populations we detected phosphorylation of YAP at serine 127 (S127) indicating LATS kinase activity. Together these point to a possible function for LATS/YAP/TAZ in normal pituitary stem cells and during tumourigenesis. Here, we have combined genetic and molecular approaches to reveal that deregulation of the pathway can promote and maintain the SOX2+ PSC fate under physiological conditions and that major disruption of this axis transforms SOX2+ PSCs into cancer-initiating cells giving rise to aggressive tumours.

Results {#s2}
=======

Sustained conditional expression of YAP during development promotes SOX2+ PSC fate {#s2-1}
----------------------------------------------------------------------------------

To determine if YAP and TAZ function during embryonic development of the pituitary, we used genetic approaches to perform gain- and loss-of-function experiments. We first expressed a constitutive active form of YAP(S127A) using the *Hesx1-Cre* driver, which drives *Cre* expression in Rathke's pouch (RP) and the hypothalamic primordium from 9.5dpc, regulated by administration of doxycycline through the reverse tetracycline-dependent transactivator (rtTA) system (*R26^rtTA/+^*; see Materials and methods for details, Scheme [Figure 1A](#fig1){ref-type="fig"}). Analyses were restricted to embryonic time points. As expected, we confirmed accumulation of total YAP protein but not of TAZ or pYAP(S127), throughout the developing pituitary and hypothalamus of *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* (hereafter YAP-TetO) embryos at 15.5dpc, but not of *Cre*-negative controls ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Likewise, the YAP downstream target *Cyr61* ([Figure 1B](#fig1){ref-type="fig"}) was also upregulated. Morphologically, YAP-TetO mutants displayed a dysplastic anterior pituitary, which was more medially compacted and lacked a central lumen, making it difficult to distinguish between the developing anterior and intermediate lobes ([Figure 1C](#fig1){ref-type="fig"}). Immunofluorescence staining against SOX2 at 15.5dpc demonstrated loss of SOX2 in the most lateral regions of control pituitaries (arrows in [Figure 1C](#fig1){ref-type="fig"}), where cells are undergoing commitment; yet mutant pituitaries had abundant SOX2 positive cells in the most lateral regions (arrowheads in [Figure 1C](#fig1){ref-type="fig"}). Immunostaining for LHX3, which is expressed in the developing anterior pituitary ([@bib49]), was used to demarcate AL and IL tissue. Staining using antibodies against lineage markers PIT1, TPIT and SF1 revealed a concomitant reduction in committed cell lineages throughout the gland ([Figure 1D](#fig1){ref-type="fig"}; PIT1 0.35% in mutants compared with 30.21% in controls (Student's t-test p\<0.0001, n = 3 for each genotype), TPIT 1.03% in mutants compared with 9.81% in controls (Student's t-test p=0.0012, n = 3 for each genotype), SF1 0.34% in mutants compared with 4.14% in controls (Student's t-test p=0.0021, n = 3 for each genotype)). We therefore conclude that sustained activation of YAP prevents lineage commitment and is sufficient to maintain the progenitor state during embryonic development.

![Regulation of YAP is required for normal morphogenesis and lineage commitment during pituitary development.\
(**A**) Schematic outlining the time course of doxycycline (DOX) treatment administered to pregnant dams from *Hesx1^Cre/+^* x *R26^rtTA/rtTA^;Col1a1^tetO-Yap/tetO-Yap^* crosses for the embryonic induction of YAP(S127A) expression in *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* (YAP-TetO) mutant embryos as well as controls that do not express YAP(S127A) (*Hesx1^+/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* controls shown here). (**B**) Immunofluorescence staining against YAP and TAZ on frontal pituitary sections at 15.5dpc confirms accumulation of YAP protein in YAP-TetO compared to control sections, but no increase in TAZ levels. RNAscope mRNA in situ hybridisation against the YAP/TAZ target *Cyr61* confirms an increase in transcripts in the anterior pituitary as well as the hypothalamus where the Cre is also active (arrows). (**C**) Haematoxylin and eosin staining of frontal pituitary sections from 15.5dpc control and YAP-TetO embryos showing pituitary dysmorphology in mutants. Immunofluorescence staining for LHX3 to mark anterior pituitary tissue and SOX2 to mark pituitary progenitors shows the persistence of SOX2 protein in lateral regions of the gland in YAP-TetO mutants (arrowheads) when they have lost SOX2 expression in controls (arrows) (magnified boxed region in SOX2, corresponding to dashed box in LHX3). (**D**) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 reveals very few cells expressing commitment markers in YAP-TetO compared to control. Graph showing quantification of committed cells of the three anterior pituitary endocrine lineages, positive for PIT1, TPIT and SF1, as a percentage of total nuclei of *Hesx1^+/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* control and *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* (YAP-TetO) mutant pituitaries at 15.5dpc (Student's *t*-test; PIT1: p\<0.0001 (\*\*\*\*), TPIT: p=0.0012 (\*\*), SF1: p=0.0021 (\*\*)). Scale bars 100 µm, 50 µm in magnified boxed regions in C. See also [Figure 1---figure supplements 1 ](#fig1s1){ref-type="fig"}[and 2](#fig1s2){ref-type="fig"}.](elife-43996-fig1){#fig1}

We did not obtain any live *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* pups at birth when treated with doxycycline from 5.5dpc (n = 5 litters). To bypass the embryonic lethality of these early inductions, we commenced doxycycline treatment from 9.5dpc, the onset of RP formation ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

*Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* pups were viable and were maintained on doxycycline until P24, at which point the experimental end point was reached due to excessive weight loss and animals had to be culled following UK Home Office Regulations. Histological analyses of pituitaries revealed multiple anterior lobe cysts per gland, localising predominantly in the ventral AL (n = 4) ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). These structures developed in YAP-accumulating regions and were lined by SOX2+ cells ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). The proportion of SOX2+ cells throughout the AL was increased, as was the percentage of SF1+ cells, whereas PIT1+ cell numbers were significantly decreased and differentiated cells of the TPIT lineage, identified by ACTH antibody staining, were unaffected ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). The total number of cycling Ki-67+ cells showed a trend towards a decrease in *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* mutants relative to controls, which did not reach significance ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). The cystic structures observed in *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* mutants were reminiscent of Rathke's cleft cyst (RCC), which is a benign developmental anomaly of the pituitary characterised by the presence of ciliated and secretory cells, expression of cytokeratins and frequent expression of p63. Immunostaining revealed that cysts were lined by cytokeratin+ cells using the AE1/AE3 pan-cytokeratin cocktail and basal cells were positive for nuclear p63 in *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* mutant pituitaries ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}). Staining using antibodies against ARL13B and Acetylated α-Tubulin (Lys40) marking cilia, revealed multi-ciliated cells along the cyst lining ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}). Combined staining using Alcian Blue and the Periodic Acid-Schiff technique (AB/PAS) to recognise mucins, detected royal blue-stained mucous cells lining the cysts ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}). Taken together, we conclude that sustained activation of YAP during embryonic and postnatal pituitary development, promotes maintenance and abnormal expansion of SOX2+ epithelia during development, resulting in the formation of cysts that resemble RCC.

Next, we generated embryos null for TAZ and conditionally lacking YAP in the *Hesx1* expression domain ([Figure 1---figure supplement 2A--E](#fig1s2){ref-type="fig"}). *Hesx1^Cre/+^;Yap^fl/fl^;Taz^-l-^* double mutants were obtained at expected ratios during embryonic stages until 15.5dpc, however the majority of *Taz^-/-^* mutants with or without compound *Yap* deletions showed lethality at later embryonic and early postnatal stages ([@bib52]) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The developing pituitary gland of *Hesx1^Cre/+^;Yap^fl/fl^;Taz^-l-^* double mutants appeared largely normal at 13.5dpc by histology ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). Immunostaining against SOX2 to mark embryonic progenitors and postnatal stem cells did not reveal differences in the spatial distribution of SOX2+ cells between double mutants compared to controls (*Hesx1^+/+^;Yap^fl/fl^;Taz^+/+^* and *Hesx1^+/+^;Yap^fl/fl^;Taz^+/-^*) at 13.5dpc, 16.0dpc ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}) or P28, even in regions devoid of both TAZ and active YAP ([Figure 1---figure supplement 2C,D](#fig1s2){ref-type="fig"}). This suggests that YAP/TAZ are not required for SOX2+ cell specification or survival. Likewise, analysis of commitment markers PIT1 and SF1 as well as ACTH to identify cells of the TPIT lineage, did not show any differences between genotypes ([Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). Together, these data suggest there is no critical requirement for YAP and TAZ during development for the specification of SOX2+ cells or lineage commitment, but that YAP functions to promote the SOX2 cell identity.

LATS, but not STK, kinases are required for normal pituitary development and differentiation {#s2-2}
--------------------------------------------------------------------------------------------

Since sustained activation of YAP led to an embryonic phenotype, we reasoned that YAP/TAZ need to be regulated during embryonic development. To determine if STK and LATS kinases are important in YAP/TAZ regulation we carried out genetic deletions in the pituitary.

Conditional deletion of *Stk3* and *Stk4* (also called *Mst2* and *Mst1*) in *Hesx1^Cre/+^;Stk3^fl/fl^;Stk4^fl/fl^* embryos did not lead to a pituitary phenotype ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). A reduction of over 75% in total STK3/4 proteins in mutants was confirmed by western blot on total lysates from *Hesx1^+/+^*;*Stk3^fl/fl^;Stk4^fl/fl^* controls and *Hesx1^Cre/+^;Stk3^fl/fl^;Stk4^fl/fl^* mutants ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Mutant pituitaries were macroscopically normal at birth ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}), and showed comparable expression patterns of TAZ, YAP, pYAP to controls lacking *Cre*, without distinct accumulation of YAP or TAZ ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). The distribution of SOX2+ cells was comparable between mutants and controls ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Normal lineage commitment was evident by immunofluorescence staining for PIT1, TPIT and SF1 at P10 ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Mutant animals remained healthy and fertile until P70, at which point pituitaries appeared histologically normal ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). Since deletion of *Stk3/4* at embryonic stages does not affect embryonic or postnatal pituitary development, we conclude these kinases are not critical for YAP/TAZ regulation in the pituitary.

![Pituitary-specific deletion of *Lats1* and *Lats2* during development leads to pituitary overgrowth and defects in lineage commitment.\
(**A**) Haematoxylin and eosin staining on sagittal sections from *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/fl^* (mutant) and *Hesx1^+/+^;Lats1^fl/fl^;Lats2^fl/fl^* (control) embryos at 13.5dpc reveals anterior pituitary dysmorphology and overgrowth in mutants (dashed outline). Immunofluorescence staining for TAZ, YAP and pYAP reveals accumulation of TAZ and YAP in overgrown mutant tissue (arrowheads, normal epithelial expression indicated by arrows in control) and lack of staining for pYAP (S127). Immunofluorescence for SOX2 shows the presence of SOX2+ progenitors throughout the abnormal tissue in mutants. (**B**) Immunofluorescence staining for late progenitor marker SOX9 shows localisation in few cells of the pituitary of mutants at 13.5dpc. Immunofluorescence staining for Ki-67 indicates cycling cells throughout the mutant pituitary. (**C**) Immunofluorescence staining for SOX2 and Endomucin (EMCN) on frontal pituitary sections at 15.5dpc shows expansion of the SOX2+ progenitor compartment compared to controls and a reduction in vasculature marked by Endomucin. Immunofluorescence for non-phosphorylated (Active) YAP shows strong expression throughout the mutant gland compared to the control. Areas of necrosis in mutant tissue indicated by asterisks. Ventral overgrowth extending into the oral cavity between the condensing sphenoid bone indicated by arrows. (**D**) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 reveals only sporadic cells expressing commitment markers in *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/fl^* mutants compared to controls. Boxes showing magnified regions. Dashed lines demarcate anterior pituitary tissue. Graph showing quantification of committed cells of the three anterior pituitary endocrine lineages, positive for PIT1, TPIT and SF1, as a percentage of total nuclei of *Hesx1^+/+^;Lats1^fl/fl^;Lats2^fl/fl^* control and *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/fl^* mutant pituitaries at 15.5dpc (Student's *t*-test; PIT1: p\<0.0001 (\*\*\*\*), TPIT: p=0.007 (\*\*), SF1: p\>0.05). Scale bars 100 µm. See also [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.](elife-43996-fig2){#fig2}

We next focused on perturbing LATS kinase function, as we have previously shown strong expression of *Lats1* in the developing pituitary and postnatal kinase activity in SOX2+ stem cells ([@bib28]). However, *Hesx1^Cre/+^;Lats1^fl/fl^* embryos showed unaffected pituitary development and normal localisation and levels of YAP and TAZ as assessed by immunofluorescence ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}) when compared with controls. mRNA in situ hybridisation against *Lats2* at P2, revealed abundant *Lats2* transcripts upon conditional deletion of *Lats1*, suggesting a compensatory upregulation of *Lats2* in the absence of LATS1 ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}), similar to previous reports of elevated YAP/TAZ signalling inducing *Lats2* expression ([@bib33]).

To overcome potential functional redundancy, we deleted both *Lats1* and *Lats2* in RP. Deletion of *Lats2* alone (*Hesx1^Cre/+^;Lats2^fl/fl^*), did not reveal any developmental morphological anomalies ([Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}) and pups were identified at normal Mendelian proportions ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Similarly, deletion of any three out of four *Lats* alleles did not affect pituitary development and were identified at normal ratios, similar to other tissues ([@bib22]). Homozygous *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/fl^* mutants were identified at embryonic stages at reduced Mendelian ratios and were absent at P0-P2, suggesting embryonic and perinatal lethality ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

Haematoxylin/eosin staining of the developing pituitary gland in *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/fl^* mutants revealed overgrowth of RP by 13.5dpc compared to controls lacking *Cre* ([Figure 2A](#fig2){ref-type="fig"}, n = 4). Total TAZ and YAP proteins accumulated throughout the developing gland in double mutants (arrowheads) but only in the SOX2+ periluminal epithelium of controls (arrows). The same regions showed a marked reduction in pYAP-S127 staining, which is observed in SOX2+ cells of the control ([Figure 2A](#fig2){ref-type="fig"}). These findings are in line with LATS1/2 normally regulating YAP and TAZ in the pituitary and demonstrate successful deletion in RP. The mutant pituitary was highly proliferative ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2F](#fig2s2){ref-type="fig"}; Ki-67 index average 47.42% ± 1.73 SEM in control versus 76.04% ± 9.11 SEM in the double mutant, p=0.0067, Student's *t*-test) and the majority of cells expressed SOX2 ([Figure 2A,C](#fig2){ref-type="fig"}) but not SOX9 ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2F](#fig2s2){ref-type="fig"}).

By 15.5dpc the pituitary was grossly enlarged and exerting a mass effect on the brain, had cysts and displayed areas of necrosis (asterisks [Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}, n = 5). Staining for Endomucin to mark blood vessels revealed poor vascularisation in *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/fl^* mutants compared to the ample capillaries seen in the control ([Figure 2C](#fig2){ref-type="fig"}), which may account for the necrosis. This could be due to a direct inhibition of vascularisation or a consequence of the rapid growth of this embryonic tumour. We frequently observed ectopic residual pituitary tissue at more caudal levels, reaching the oral epithelium and likely interfering with appropriate fusion of the sphenoid, similar to other phenotypes involving pituitary enlargement (arrows [Figure 2C](#fig2){ref-type="fig"}) ([@bib3]; [@bib46]; [@bib13]). Immunofluorescence to detect active (non-phosphorylated) YAP revealed abundant staining throughout the pituitary at 15.5dpc, compared to the control where active YAP localises in the SOX2 epithelium ([Figure 2C](#fig2){ref-type="fig"}). Immunofluorescence using specific antibodies against lineage commitment markers PIT1, TPIT and SF1 at 15.5dpc revealed very few cells expressing PIT1, TPIT and SF1 in the double mutant ([Figure 2D](#fig2){ref-type="fig"}; PIT1 9.14% in mutants compared with 51.4% in controls (Student's *t*-test p\<0.0001); TPIT 4.0% in mutants compared with 11.4% in controls (Student's *t*-test p\<0.007); SF1 2.1% in mutants compared with 6.5% in controls (Student's *t*-test p\>0.05) n = 3 mutants and five controls), suggesting failure to commit into the three lineages. These data suggest that the LATS/YAP/TAZ axis is required for normal embryonic development of the anterior pituitary and that LATS1/2 kinases control proliferation of SOX2+ progenitors and their progression into the three committed lineages.

Loss of LATS kinases results in carcinoma-like murine tumours {#s2-3}
-------------------------------------------------------------

Postnatal analysis of *Hesx1^Cre/+^;Lats1^fl/fl^* pituitaries revealed that by P56, despite developing normally during the embryonic period, all glands examined exhibited lesions of abnormal morphology consisting of overgrowths, densely packed nuclei and loss of normal acinar architecture (n = 15). To minimise the likely redundancy by LATS2 seen at embryonic stages, we generated *Lats1* mutants additionally haploinsufficient for *Lats2* (*Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/+^*). These pituitaries also developed identifiable lesions accumulating YAP and TAZ ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), which were observed at earlier time points (P21 n = 4), the earliest being 10 days, indicating increased severity. The number of lesions observed per animal was similar between the two models at P56 (3--8 per animal). Deletion of *Lats2* alone (*Hesx1^Cre/+^;Lats2^fl/fl^*), which is barely expressed in the wild type pituitary, did not result in any defects ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We focused on the *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/+^* double mutants for further analyses.

Histological examination of *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/+^* pituitaries confirmed the abnormal lesions were tumours, characterised by frequent mitoses, focal necrosis, and a focal squamous differentiation, as well as the occasional presence of cysts ([Figure 3A](#fig3){ref-type="fig"}). These lesions were identical to those in *Hesx1^Cre/+^;Lats1^fl/fl^* pituitaries (not shown). These tumours accumulated YAP/TAZ and upregulated expression of targets *Cyr61* and *Ctgf* ([Figure 3B](#fig3){ref-type="fig"}), confirming the validity of the genetic manipulation ([Figure 3B](#fig3){ref-type="fig"}). Tumours were also frequently observed in the anterior and intermediate lobe ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Analysis of proliferation by Ki-67 immunostaining revealed an elevated mitotic index of 7--28% in tumours (mean 15.46, SEM ±2.74), compared to 2.97% (SEM ±1.2) mean in control pituitaries not carrying the *Lats1* deletion ([Figure 3C](#fig3){ref-type="fig"}).

![Pituitary specific loss of *Lats1* leads to tumour formation.\
(**A**) Haematoxylin and eosin staining of frontal sections from *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/+^* (mutant) and control pituitaries at P56 demonstrates overgrown tumourigenic regions in mutants. These show focal necrosis, cysts and a squamous morphology (magnified regions) not seen in controls. Asterisk indicates necrosis. (**B**) Immunofluorescence staining for TAZ, YAP and pYAP(S127) show accumulation of TAZ and YAP but not pYAP in the mutant but not in the control. RNAscope mRNA in situ hybridisation against YAP/TAZ targets *Ctgf* and *Cyr61* reveals an increase in transcripts on mutant tissue compared to control. (**C**) Graph of the proliferation index in control and mutant samples at P56 shows a significant increase in cycling cells in the *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/+^* mutant pituitaries compared to controls (control percentage Ki-67: 2.967 ± 1.2 SEM, n = 3; mutant: 15.46 ± 2.74 n = 7. p=0.0217 (\*), two-tailed *t*-test). Images show representative examples of Ki-67 immunofluorescence staining. (**D**) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 shows the near absence of committed cells in tumours. (**E**) Immunofluorescence staining for pituitary stem cell markers SOX2 and SOX9 reveal that tumour lesions have abundant positive cells compared to the control, while Endomucin (EMCN) staining shows poor vascularisation. (**F**) The marginal zone epithelium of *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/+^* mutant pituitaries develops invaginations as seen by haematoxylin and eosin staining. Immunofluorescence staining against SOX2 shows the maintenance of a single-layered epithelium. Scale bars 100 µm. Boxes indicate magnified regions. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.](elife-43996-fig3){#fig3}

In keeping with the morphological evidence of epithelial differentiation ([Figure 3A](#fig3){ref-type="fig"}), the tumours were positive for cytokeratins using AE1/AE3 (multiple keratin cocktail) ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Furthermore, the tumours showed focal morphological evidence of squamous differentiation and showed positive nuclear p63 staining, frequently expressed in squamous carcinomas ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). In contrast, the tumours did not show immunohistochemical evidence of adenomas, that is, they were negative for neuroendocrine markers, which all types of adenomas are typically positive for: the neuroendocrine marker synaptophysin and neuron-specific enolase ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). The lesions were also negative for chromogranin A, a neuroendocrine granule marker often expressed in clinically non-functioning pituitary adenomas. Tumours were also negative for vimentin, expressed by spindle cell oncocytoma, an uncommitted posterior pituitary tumour ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). Moreover, immunostaining against PIT1, TPIT and SF1 showed only sparse positive cells within the lesions, suggesting lack of commitment into endocrine precursors and supporting the undifferentiated nature of the tumour cells ([Figure 3D](#fig3){ref-type="fig"}). Consistent with a tumourigenic phenotype, and role for LATS1 genomic stabilisation ([@bib41]), staining for gamma-H2A.X detected elevated DNA damage in cells of the mutant pituitaries compared with controls ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). The absence of adenoma or oncocytoma markers together with the histological appearance, observation of focal necrosis and a high mitotic index support the features of squamous carcinoma.

SOX2+ cells are the cell of origin of the tumours {#s2-4}
-------------------------------------------------

Tumour regions were mostly composed of SOX2 positive cells, a sub-population of which also expressed SOX9 ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}; 85--97% of cells, 7 tumours across four pituitaries). Close examination of the marginal zone epithelium, a major SOX2+ stem cell niche of the pituitary, revealed a frequent 'ruffling' resembling crypts, likely generated through over-proliferation of the epithelial stem cell compartment ([Figure 3F](#fig3){ref-type="fig"}). To determine if the cell of origin of the tumourigenic lesions is a deregulated SOX2+ stem cell, we carried our specific deletion of LATS1/2 in postnatal SOX2+ cells using the tamoxifen-inducible *Sox2-CreERT2* driver, combined with conditional expression of membrane-GFP in targeted cells (*Sox2^CreERT2/+^;Lats1^fl/fl^;Lats2^fl/+^;R26^mTmG/+^*).

Tamoxifen induction at P5 or P21, led to abnormal lesions in the anterior pituitary within three months in all cases. We focused our analyses on inductions performed at P5, from which time point all animals developed lesions by P35 ([Figure 4A](#fig4){ref-type="fig"}). Similar to observations in *Hesx1^Cre/+^;Lats1^fl/fl^;Lats2^fl/+^* animals, these areas strongly accumulated YAP and TAZ ([Figure 4B](#fig4){ref-type="fig"}), activated expression of targets *Cyr61* and *Ctgf*, displayed ruffling of the AL epithelium ([Figure 4C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}) and lacked lineage commitment markers ([Figure 4D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). These lesions showed a similar marker profile to *Hesx1-Cre*-targeted tumours, with positive p63 and AE1/AE3 staining ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Lineage tracing confirmed expression of membrane GFP in tumourigenic lesions, characterised by the accumulation of YAP and expansion of SOX2+ cells, suggesting they were solely derived from SOX2+ cells ([Figure 4E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Taken together, our data support that LATS kinase activity is required to regulate the pituitary stem cell compartment. Loss of LATS1 is sufficient to drive deregulation of SOX2+ pituitary stem cells, generating highly proliferative non-functioning tumours with features of carcinomas.

![SOX2+ pituitary stem cells are the cell-of-origin of tumours generated in the absence of *Lats1*.\
(**A**) Schematic outlining the experimental time line of inductions in *Sox2^CreERT2/+^;Lats1^fl/fl^;Lats2^fl/+^* (mutant) and *Sox2^+/+^;Lats1^fl/fl^;Lats2^fl/+^* (control) animals. Representative images of haematoxylin and eosin staining of frontal sections of control and mutant pituitaries at P35, revealing a hyperplastic anterior pituitary in the mutant with areas of necrosis (asterisks). (**B**) Immunofluorescence staining reveals tumourigenic lesions in *Sox2^CreERT2/+^;Lats1^fl/fl^;Lats2^fl/+^* that display increased levels of TAZ and YAP staining compared to the control. (**C**) RNAscope mRNA in situ hybridisation against *Ctgf* and *Cyr61* shows elevated transcripts in tumourigenic lesions. Insets (**i**) and (ii) show invaginations in the epithelium of the mutant. (**D**) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 showing a reduction in staining in tumourigenic lesions compared to control pituitaries. (**E**) Lineage tracing of SOX2+ cells in *Sox2^CreERT2/+^;Lats1^fl/fl^;Lats2^fl/+^R26^mTmG/+^* reveals that tumour regions accumulating YAP as seen by immunofluorescence, are composed of GFP+ cells at P35. Scale bars 500 µm in A; 100 µm in B, D, E; 250 µm in C. See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.](elife-43996-fig4){#fig4}

YAP expression is sufficient to activate pituitary stem cells {#s2-5}
-------------------------------------------------------------

Conditional deletion of LATS1/2 kinases in the pituitary has revealed how these promote an expansion of SOX2+ stem cells in the embryonic and postnatal gland at the expense of differentiation. To establish if this effect was mediated through YAP alone, we used the tetracycline-controlled conditional YAP-TetO system to promote YAP (S127A) protein levels in postnatal pituitaries of *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* mice. We treated YAP-TetO animals with doxycycline from P21 to P105 (12 week treatment, [Figure 5A](#fig5){ref-type="fig"}). We did not observe the formation of tumours at any stage analysed (n = 12, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Similarly, we did not observe the formation of lesions when treating from P5. This is in contrast with the unequivocal tumour formation observed in *Sox2^CreERT2/+^;Lats1^fl/fl^;Lats2^fl/+^* mice. Elevation of YAP protein levels was confirmed following three weeks of doxycycline treatment (P42), displaying patchy accumulation, likely a result of genetic recombination efficiencies ([Figure 5B](#fig5){ref-type="fig"}). Consistent with pathway activation, there was robust elevation in the expression of transcriptional targets *Cyr61* and *Ctgf* following treatment ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), however at significantly lower levels compared to *Sox2^CreERT2/+^;Lats1^fl/fl^;Lats2^fl/+^* deletions ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}), and there was no elevation in phosphorylated inactive YAP ([Figure 5B](#fig5){ref-type="fig"}).

![Postnatal expression of constitutively active YAP increases leads to an activation of SOX2+ pituitary stem cells.\
(**A**) Schematic outlining the time course of doxycycline (DOX) treatment administered to *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* (YAP-TetO) and *Hesx1^+/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* controls to drive expression of YAP-S127A in mutant pituitaries. (**B**) At P42 (3 weeks of treatment), immunofluorescence staining on frontal anterior pituitary sections detects strong total YAP expression in YAP-TetO mutants compared to the control and no increase in pYAP(S127). Immunofluorescence for SOX2 and SOX9 reveals an expanded population of stem cells in YAP-TetO compared to control (quantification in F). (**C**) Graph showing the percentage of double Ki-67+;SOX2+ cells as a proportion of the total SOX2+ (p*=*0.027 (\*)) or Ki-67+ (p*=*0.006 (\*\*)) populations at P42 (n = 3 pituitaries per genotype). There is an increase in the numbers of cycling SOX2 cells in YAP-TetO mutant compared to controls. The image shows a representative example of double immunofluorescence staining against Ki-67 and SOX2 in a control and YAP-TetO section. (**D**) Schematic outlining the time course of doxycycline (DOX) treatment administered to *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* (YAP-TetO) and *Hesx1^+/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* controls to drive expression of YAP-S127A in mutant pituitaries for three weeks, followed by a three-week recovery period in the absence of DOX. (**E**) Immunofluorescence staining against YAP, SOX2 and SOX9 on control and YAP-TetO pituitaries treated as in D, shows comparable expression of YAP, SOX2 and SOX9 between genotypes. (**F**) Graph of quantification of SOX2+ cells as a percentage of total nuclei in control and YAP-TetO pituitaries at P42 p*=*0.0014 (\*\*); P63 p*=*0.0044 (\*\*); P105 p*\<*0.0001(\*\*\*\*) (n = 3 pituitaries per genotype). Following the Recovery treatment scheme in D, there is no significant difference in the numbers of SOX2+ cells between genotypes. (**G**) Schematic outlining the time course of tamoxifen induction and doxycycline (DOX) treatment administered to *Sox2^CreERT2/+^;R26^rtTA/mTmG^;Col1a1^tetO-Yap/+^* (mutant) and *Sox2^CreERT2/+^;R26^mTmG/+^;Col1a1^+/+^* (control) animals to drive expression of YAP-S127A in SOX2+ cells of mutants. (**H**) Lineage tracing of SOX2+ cells and immunofluorescence staining against SOX2 and GFP shows an expansion of GFP+ cells compared to controls at P63, where a proportion of cells are double-labelled. (**I**) Immunofluorescence staining against commitment markers PIT1, SF1 and terminal differentiation marker ACTH (TPIT lineage) together with antibodies against GFP detects double-labelled cells (arrows) across all three lineages in *Sox2^CreERT2/+^;R26^rtTA/mTmG^;Col1a1^tetO-Yap/+^* pituitaries following the recovery period. Graph of quantification of GFP+;PIT1+, GFP+;SF1+ and GFP+;ACTH+ cells as a percentage of total GFP+ cells in *Sox2^CreERT2/+^;R26^rtTA/mTmG^;Col1a1^tetO-Yap/+^* pituitaries at P63. Scale bars 100 µm. Data in C. and F. represented as mean ±SEM, analysed with Two-Way ANOVA with Sidak's multiple comparisons. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.](elife-43996-fig5){#fig5}

Immunofluorescence against SOX2 demonstrated a significant increase in the number of SOX2+ cells as a proportion of the anterior pituitary ([Figure 5B,F](#fig5){ref-type="fig"}; 18.0% compared to 12.1% in controls, p=0.0014), a finding recapitulated by SOX9 that marks a subset of the SOX2 population ([Figure 5B](#fig5){ref-type="fig"}). This increase in the percentage of SOX2+ cells was maintained at all stages analysed ([Figure 5F](#fig5){ref-type="fig"}) and did not affect the overall morphology of the pituitary. At P42 we observed a significant increase in proliferation among the SOX2+ pituitary stem cells from 3% in controls to 15% in mutants (p=0.027). SOX2+ cells make up 10% of all cycling cells (Ki-67%) in normal pituitaries, however in mutants this increased to 25%, suggesting a preferential expansion of the SOX2+ population, rather than an overall increase in proliferation ([Figure 5C](#fig5){ref-type="fig"}). No additional marked differences were observed in samples analysed at P63 (6 weeks of treatment, n = 3), however longer treatment (P21 to P105) resulted in sporadic regions of expanded SOX2+ cells ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). These regions did not express the commitment marker PIT1 and were identifiable by haematoxylin/eosin staining. In contrast to tumour lesions generated following loss of LATS kinases, these were not proliferative, were positive for pYAP and did not accumulate high levels of YAP/TAZ (n = 6 lesions). Together these results suggest that the sustained expression of constitutive active YAP can activate the proliferation of SOX2 stem cells, but in contrast to deletion of LATS1, this alone is not oncogenic.

To establish if the expansion of pituitary stem cells following forced expression of YAP is reversible, we administered doxycycline to YAP-TetO animals for three weeks (P21 to P42) by which point there is a robust response, followed by doxycycline withdrawal for three weeks (until P63) to allow sufficient time for YAP levels to return to normal (scheme [Figure 5D](#fig5){ref-type="fig"}). Immunofluorescence against total YAP protein confirmed restoration of the normal YAP expression pattern and levels after recovery ([Figure 5E](#fig5){ref-type="fig"}), and mRNA in situ hybridisation detected a reduction in expression of YAP/TAZ targets *Cyr61* and *Ctgf* ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). Following recovery from high levels of YAP, the number of SOX2+ cells reduced to comparable levels as in controls (around 10% of the total anterior pituitary) ([Figure 5E,F](#fig5){ref-type="fig"}). This suggests that the effects of YAP overexpression on the stem cell population are transient following three weeks of treatment ([Figure 5F](#fig5){ref-type="fig"}).

Finally, to determine if SOX2+ cells could differentiate into hormone-producing cells after the reduction in YAP levels, we expressed constitutive active YAP only in SOX2+ cells while lineage tracing this population (*Sox2^CreERT2/+^;R26^rtTA/mTmG^;Col1a1^tetO-Yap/+^*). We induced SOX2+ cells by low-dose tamoxifen administration at P21 and treated with doxycycline for three weeks, followed by doxycycline withdrawal for a further three weeks ([Figure 5G](#fig5){ref-type="fig"}). Larger clones of SOX2 derivatives were observed at P63 in *Sox2^CreERT2/+^;R26^rtTA/mTmG^;Col1a1^tetO-Yap/+^* animals compared to controls, and these still contained SOX2+ cells ([Figure 5H](#fig5){ref-type="fig"}). Following withdrawal, we were able to detect GFP+ derivatives of SOX2+ cells, which had differentiated into the three lineages (PIT1, SF1 and ACTH, marking corticotrophs of the TPIT lineage) ([Figure 5I](#fig5){ref-type="fig"}). Taken together, these findings confirm that sustained expression of YAP is sufficient to maintain the SOX2+ state and promote activation of normal SOX2+ pituitary stem cells in vivo, driving expansion of this population.

Discussion {#s3}
==========

Here we establish that regulation of LATS/YAP/TAZ signalling is essential during anterior pituitary development and can influence the activity of the stem/progenitor cell pool. LATS kinases, mediated by YAP and TAZ, are responsible for controlling organ growth, promoting an undifferentiated state and repressing lineage commitment. Loss of both *Lats1* and *Lats2*, encoding potent tumour suppressors, leads to dramatic tissue overgrowth during gestation, revealing a function for these enzymes in restricting growth during pituitary development. The involvement of YAP/TAZ and dysfunction of the kinase cascade is emerging in multiple paediatric cancers, which are often developmental disorders ([@bib1]).

Loss of *LATS1* heterozygosity has been reported in a range of human tumours ([@bib23]; [@bib9]; [@bib51]; [@bib31]) leading to an increase in YAP/TAZ protein levels. Previous global deletion of *Lats1* in mice resulted in a variety of soft tissue sarcomas and stromal cell tumours ([@bib50]). The anterior lobe of these animals appeared hyperplastic with poor endocrine cell differentiation leading to combined hormone deficiencies, but the presence of tumours was not noted. We report that loss of *Lats1* alone is sufficient to drive anterior and intermediate lobe tumour formation. This phenotype is accelerated following additional deletion of one copy of *Lats2*. Phenotypically identical tumour lesions were generated when the genetic deletions were carried out embryonically in RP, or at postnatal stages. Interestingly, tissue-specific loss of *Stk3* and *Stk4*, which regulate LATS activation in other tissues ([@bib18]), did not lead to any pituitary defects despite reduction in STK3/4 levels. These data suggest that perhaps the residual activity of STK3/4 is sufficient for LATS1/2 activation. Alternatively, regulation of LATS1/2 by kinases other than STK3/4 is possible in the pituitary, meaning deletion of *Stk3/4* alone is insufficient to result in significant LATS function impairment. Similar situations have been reported in other organs where LATS are functioning ([@bib18]). The resulting non-secreting tumours in our mouse models are composed predominantly of SOX2+ stem cells and display signs of squamous differentiation. Rare cases of squamous cell carcinoma have been reported as primary pituitary tumours ([@bib45]), but more frequently, arising within cysts that are normally non-neoplastic epithelial malformations ([@bib25]; [@bib38]). In the embryonic YAP-TetO model, where constitutive active YAP (S127A) was expressed during pituitary development, cysts phenocopying Rathke's cleft cyst, develop by postnatal stages. Target elevation is not as high in YAP-TetO pituitaries, as following the deletion of LATS1/2, indicating that signalling levels are likely to be critical for progression between these phenotypes.

Although human pituitary carcinomas are only diagnosed as such after metastasis, the tumours generated in our LATS1/2 mouse models fit their histopathological profile. Genetic lineage tracing identified SOX2+ cells as the cell of origin of the tumours; this observation could have ramifications regarding involvement of the LATS/YAP/TAZ pathway in the establishment or progression of human pituitary tumours composed of uncommitted cells. In cancer stem cells of osteosarcoma and glioblastoma, SOX2 antagonises upstream Hippo activators, leading to enhanced YAP function ([@bib5]). We recently reported enhanced expression of YAP/TAZ in a range of non-functioning human pituitary tumours, compared to functioning adenomas, and that *Lats1* knock-down in GH3 pituitary mammosomatotropinoma cells results in repression of the *Gh* and *Prl* promoters ([@bib55]). Therefore, YAP/TAZ, perhaps in a positive feedback loop with SOX2, are likely to function both to promote the maintenance of an active pituitary stem cell state as well as to inhibit differentiation.

By dissecting the downstream requirement for YAP in pituitary regulation by the LATS/YAP/TAZ axis, we found that expression of constitutively active YAP (S127A) is sufficient to push SOX2+ pituitary stem cells into an activated state, leading to expansion of the stem cell cohort (see Model, [Figure 6](#fig6){ref-type="fig"}). YAP has previously been indicated to promote the stem cell state in other tissues, for example pancreas, neurons and mammary glands ([@bib39]). However, this does not fully recapitulate the LATS deletion phenotypes, as it did not lead to the formation of tumours during the time course of YAP activation (12 weeks). Interestingly, since the levels of target activation are significantly greater in *Lats1/2* deletions that in YAP-TetO activation, initiation of tumourigenesis may be associated with levels of signalling rising above a threshold. However, the temporal control of expressing the mutation is critical, as seen in other tumour models ([@bib15]). Instead, the findings identify an isolated role for YAP in promoting the expansion of the SOX2+ stem cell pool and restoring their proliferative potential to levels akin to the most active state during postnatal pituitary growth. Activity of YAP/TAZ is reduced in dense tissues, resulting in a decrease in stemness. One mechanism through which this is achieved is by crosstalk with other signalling pathways regulating stem cell fate ([@bib40]; [@bib16]). For example, a decrease in YAP/TAZ activity removes inhibition on Notch signalling, resulting in higher levels of differentiation and a drop in stem cell potential ([@bib53]). In the pituitary, Notch plays a role in the maintenance of the SOX2 stem cell compartment and is involved in regulating differentiation ([@bib62]; [@bib35]; [@bib10]; [@bib6]). The downstream mechanisms of YAP action on SOX2+ pituitary stem cells, as well as the likely crosstalk with other signalling pathways remain to be explored.

![Model of stem cell activity following regulation by the LATS/YAP/TAZ cascade in the anterior pituitary.\
SOX2+ pituitary stem cells express YAP and TAZ (green spheres). During normal developmental and postnatal expansion (normal regulation), pituitary stem cells are maintained as a balanced pool while generating endocrine cells of three committed lineages (red, blue, yellow). Expression of constitutively active YAP-S127A in pituitary stem cells leads to an elevation in target gene expression, an expansion of pituitary stem cell numbers and maintenance of the SOX2+ state, preventing lineage commitment. When YAP-S127A expression ceases, commitment into the endocrine lineages takes place. Genetic deletion of LATS kinases (LATS1 as well as one or two copies of LATS2), results in YAP and TAZ accumulation, major elevation in target gene expression, repression of lineage commitment, continued expansion of SOX2+ cells and tumour formation.](elife-43996-fig6){#fig6}

In summary, our findings highlight roles for LATS/YAP/TAZ in the regulation of pituitary stem cells, where fine-tuning of their expression can make the difference between physiological stem cell re-activation and tumourigenesis, of relevance to other organs. We reveal this axis is involved in the control of cell fate commitment, regulation of regenerative potential and promotion of tumourigenesis. These findings can aid in the design of treatments against pituitary tumours and in regenerative medicine approaches targeting the regulation of endogenous stem cells.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\      Designation                                   Source or reference                                               Identifiers                                                                         Additional\
  (species) or\                                                                                                                                                                                                          information
  resource                                                                                                                                                                                                               
  ------------------ --------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------- -------------
  Genetic reagent\   *Hesx1^Cre/+^*                                [@bib2]                                                           RRID:[MGI:5314529](https://scicrunch.org/resolver/MGI:5314529)                      
  (*M. musculus*)                                                                                                                                                                                                        

  Genetic reagent\   *Sox2^CreERT2/+^*                             [@bib4]                                                           MGI:5512893                                                                         
  (*M. musculus*)                                                                                                                                                                                                        

  Genetic reagent\   *Lats1^fl/fl^*                                Jackson Laboratory                                                Stock \#: 024941, RRID: [MGI:5568576](https://scicrunch.org/resolver/MGI:5568576)   
  (*M. musculus*)                                                                                                                                                                                                        

  Genetic reagent\   *Lats2^fl/fl^*                                Jackson Laboratory                                                Stock \#: 025428, RRID: [MGI:5568577](https://scicrunch.org/resolver/MGI:5568577)   
  (*M. musculus*)                                                                                                                                                                                                        

  Genetic reagent\   *Stk4^fl/fl^;Stk3^fl/fl^*                     Jackson Laboratory                                                Stock \#: 017635, RRID: [MGI:5301573](https://scicrunch.org/resolver/MGI:5301573)   [@bib29]
  (*M. musculus*)                                                                                                                                                                                                        

  Genetic reagent\   R26^rtTA/+^                                   Jackson Laboratory                                                Stock: \#: 016999\                                                                  [@bib56]
  (*M. musculus*)                                                                                                                    RRID: [MGI:5292520](https://scicrunch.org/resolver/MGI:5292520)                     

  Genetic reagent\   *Col1a1^tetO-Yap/+^*                          [@bib20]                                                          MGI:5430522                                                                         
  (*M. musculus*)                                                                                                                                                                                                        

  Genetic reagent\   *R26^mTmG/+^*                                 JacksonLaboratory                                                 Stock \#: 007576\                                                                   [@bib34]
  (*M. musculus*)                                                                                                                    RRID:[MGI:3722405](https://scicrunch.org/resolver/MGI:3722405)                      

  Genetic reagent\   *Taz^-/-^*                                    Jackson Laboratory                                                Stock \#: 011120, RRID: [MGI:4420900](https://scicrunch.org/resolver/MGI:4420900)   [@bib52]
  (*M. musculus*)                                                                                                                                                                                                        

  Genetic reagent\   *Yap^fl/fl^*                                  [@bib48]                                                          MGI:5316446                                                                         
  (*M. musculus*)                                                                                                                                                                                                        

  Antibody           Rabbit polyclonal anti-TAZ                    Atlas Antibodies                                                  Cat\# HPA007415\                                                                    IF: 1:1000
                                                                                                                                     RRID:[AB_1080602](https://scicrunch.org/resolver/AB_1080602)                        

  Antibody           Rabbit polyclonal anti-YAP                    Cell Signaling\                                                   Cat\# 4912S\                                                                        IF: 1:1000
                                                                   Technology                                                        RRID:[AB_2218911](https://scicrunch.org/resolver/AB_2218911)                        

  Antibody           Rabbit polyclonal anti-pYAP                   Cell Signaling\                                                   Cat\# 4911S\                                                                        IF: 1:1000
                                                                   Technology                                                        RRID:[AB_2218913](https://scicrunch.org/resolver/AB_2218913)                        

  Antibody           Rabbit polyclonal\                            Abcam                                                             Cat\# ab97959\                                                                      IF: 1:2000
                     anti-SOX2                                                                                                       RRID:[AB_2341193](https://scicrunch.org/resolver/AB_2341193)                        

  Antibody           Rat monoclonal\                               Abcam                                                             Cat\# ab106100\                                                                     IF: 1:1000
                     anti-EMCN\                                                                                                      RRID:[AB_10859306](https://scicrunch.org/resolver/AB_10859306)                      
                     (V.7C7.1)                                                                                                                                                                                           

  Antibody           Chicken polyclonal anti-GFP                   Abcam                                                             Cat\# ab13970\                                                                      IF: 1:300
                                                                                                                                     RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)                          

  Antibody           Goat\                                         Immune Systems\                                                   Cat\# GT15098\                                                                      IF: 1:250
                     polyclonal anti-\                             Limited                                                           RRID:[AB_2732043](https://scicrunch.org/resolver/AB_2732043)                        
                     SOX2                                                                                                                                                                                                

  Antibody           Rabbit monoclonal anti-Ki-67                  Abcam                                                             Cat\# ab16667\                                                                      IF: 1:300
                                                                                                                                     RRID:[AB_302459](https://scicrunch.org/resolver/AB_302459)                          

  Antibody           Rabbit\                                       Proteintech\                                                      Cat\# 17711--1-AP,\                                                                 IF: 1:100
                     polyclonal anti-\                             Group                                                             RRID:[AB_2060867](https://scicrunch.org/resolver/AB_2060867)                        
                     ARL13B                                                                                                                                                                                              

  Antibody           Mouse monoclonal anti-Acetylated-αTUB         Sigma-Aldrich                                                     Cat\# MABT868                                                                       IF: 1:200

  Antibody           Rabbit monoclonal anti-SOX9                   Abcam                                                             Cat\# ab185230\                                                                     IF: 1:300
                                                                                                                                     RRID:[AB_2715497](https://scicrunch.org/resolver/AB_2715497)                        

  Antibody           Rabbit monoclonal\                            Abcam                                                             Cat\# ab205270                                                                      IF: 1:300
                     anti-Active YAP\                                                                                                                                                                                    
                     EPR19812                                                                                                                                                                                            

  Antibody           Rabbit\                                       Prof. S Rhodes\                                                                                                                                       IF: 1:1000
                     polyclonal anti-\                             (Indiana University)                                                                                                                                  
                     PIT1                                                                                                                                                                                                

  Antibody           Rabbit\                                       Prof. J Drouin\                                                                                                                                       IF: 1:1000
                     polyclonal anti-\                             (Montreal IRCM)                                                                                                                                       
                     TPIT                                                                                                                                                                                                

  Antibody           Mouse monoclonal\                             Life Technologies\                                                Cat\# N1665\                                                                        IF: 1:200
                     anti-SF1                                      (Thermo Fisher\                                                   RRID:[AB_2532209](https://scicrunch.org/resolver/AB_2532209)                        
                                                                   Scientific)                                                                                                                                           

  Antibody           Rabbit polyclonal anti-\                      Abcam                                                             Cat\# ab2893\                                                                       IF: 1:1000
                     gamma H2A.X\                                                                                                    RRID:[AB_303388](https://scicrunch.org/resolver/AB_303388)                          
                     (phospho S139)                                                                                                                                                                                      

  Antibody           Rabbit\                                       Bethyl Laboratories                                               Cat\# A300-466A\                                                                    WB: 1:5000
                     polyclonal anti-\                                                                                               RRID:[AB_2148394](https://scicrunch.org/resolver/AB_2148394)                        
                     STK3/4                                                                                                                                                                                              

  Antibody           Mouse monoclonal anti-Cyclophilin B\          R and D Systems                                                   Cat\# MAB5410\                                                                      WB: 1:1000
                     (Clone\# 549205)                                                                                                RRID:[AB_2169416](https://scicrunch.org/resolver/AB_2169416)                        

  Antibody           Rabbit monoclonal\                            Cell Signaling\                                                   Cat\# 5741\                                                                         IF: 1:300
                     anti-Vimentin\                                Technology                                                        RRID:[AB_10695459](https://scicrunch.org/resolver/AB_10695459)                      
                     (D21H3)                                                                                                                                                                                             

  Antibody           Biotinylated Goat\                            Abcam                                                             Cat\# ab6720\                                                                       IF: 1:350
                     polyclonal anti-\                                                                                               RRID:[AB_954902](https://scicrunch.org/resolver/AB_954902)                          
                     rabbit                                                                                                                                                                                              

  Antibody           Goat polyclonal anti-chicken\                 Life Technologies\                                                Cat\# A11039\                                                                       IF: 1:300
                     Alexa Fluor 488                               (Thermo Fisher\                                                   RRID:[AB_2534096](https://scicrunch.org/resolver/AB_2534096)                        
                                                                   Scientific)                                                                                                                                           

  Antibody           Goat polyclonal anti-rat Alexa Fluor 555      Life Technologies\                                                Cat\# A21434\                                                                       IF: 1:300
                                                                   (Thermo Fisher Scientific)                                        RRID:[AB_2535855](https://scicrunch.org/resolver/AB_2535855)                        

  Antibody           Biotinylated Goat polyclonal anti-mouse       Abcam                                                             Cat\# ab6788\                                                                       IF: 1:350
                                                                                                                                     RRID:[AB_954885](https://scicrunch.org/resolver/AB_954885)                          

  Antibody           Donkey polyclonal anti-goat Alexa Fluor 488   Abcam                                                             Cat\# ab150133                                                                      IF: 1:300

  Antibody           Streptavidin Alexa Fluor 555                  Life Technologies                                                 Cat\# S21381\                                                                       IF: 1:500
                                                                                                                                     RRID:[AB_2307336](https://scicrunch.org/resolver/AB_2307336)                        

  Antibody           Goat HRP-linked anti-rabbit                   Cell Signaling Technology                                         Cat\# 7074\                                                                         WB: 1:2000
                                                                                                                                     RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)                        

  Antibody           Goat HRP-linked anti-mouse                    Cell Signaling Technology                                         Cat\# 7076\                                                                         WB: 1:2000
                                                                                                                                     RRID:[AB_330924](https://scicrunch.org/resolver/AB_330924)                          

  Antibody           Mouse monoclonal anti-AE1/AE3                 Dako                                                              Cat\# M351529                                                                       IHC: 1:100

  Antibody           Mouse monoclonal anti-Chromogranin            Dako                                                              Cat\# M086901                                                                       IHC: 1:400

  Antibody           Mouse monoclonal anti-NCAM                    Novocastra                                                        Cat\# NCL-L-CD56-504                                                                IHC 1:15

  Antibody           Mouse monoclonal anti-NSE                     Dako                                                              Cat\# M087329                                                                       IHC 1:1000

  Antibody           Mouse monoclonal anti-p63                     A Menarini\                                                       Cat\# MP163                                                                         IHC 1:100
                                                                   Diagnostics                                                                                                                                           

  Antibody           Mouse monoclonal anti-Synaptophysin           Dako                                                              Cat\# M731529\                                                                      IHC 1:2
                                                                                                                                     RRID:[AB_2687942](https://scicrunch.org/resolver/AB_2687942)                        

  Commercial\        TSA kit                                       Perkin Elmer                                                      Cat\# NEL753001KT                                                                   
  assay or kit                                                                                                                                                                                                           

  Commercial\        TSA Blocking Reagent                          Perkin Elmer                                                      Cat\# FP1020                                                                        
  assay or kit                                                                                                                                                                                                           

  Commercial\        ABC kit                                       Vector Laboratories                                               Cat\# Vector PK-6100\                                                               
  assay or kit                                                                                                                       RRID:[AB_2336819](https://scicrunch.org/resolver/AB_2336819)                        

  Commercial\        BCA assay                                     Thermo Fisher                                                     Cat\# 23227                                                                         
  assay or kit                                                                                                                                                                                                           

  Commercial\        UltraView Universal DAB Detection Kit         Ventana Medical Systems                                           Cat\# 760--500                                                                      
  assay or kit                                                                                                                                                                                                           

  Commercial\        VectaFluor Excel R.T.U. Antibody\             Vector Laboratories                                               Cat\# DK-2488\                                                                      
  assay or kit       Kit, DyLight 488 Anti-Mouse                                                                                     RRID:[AB_2336775](https://scicrunch.org/resolver/AB_2336775)                        

  Chemical\          Doxycycline hyclate                           Alfa Aesar                                                        Cat\# J60579                                                                        2 mg/ml
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Sucrose                                       Sigma-Aldrich                                                     Cat\# S0389                                                                         10 mg/ml
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Tamoxifen                                     Sigma-Aldrich                                                     Cat\# T5648                                                                         0.15 mg/g
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Hoechst 33342                                 Life Technologies                                                 Cat\# H3570                                                                         1:10000
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Laemmli buffer                                Bio-Rad                                                           Cat\# 1704156                                                                       
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Clarity Western ECL Substrate                 Bio-Rad                                                           Cat\# 170--5060                                                                     
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Alcian Blue                                   Alfa Aeser                                                        Cat\# J60122                                                                        1%
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Acetic acid                                   VWR                                                               Cat\# 20103                                                                         3%
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Periodic acid                                 VWR                                                               Cat\# 29460                                                                         1%
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Chemical\          Schiff's reagent                              Thermo Fisher Scientific                                          Cat\# 88017                                                                         
  compound,\                                                                                                                                                                                                             
  drug                                                                                                                                                                                                                   

  Software,\         GraphPad Prism                                GraphPad Software ([www.graphpad.com](http://www.graphpad.com))   RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)                        
  algorithm                                                                                                                                                                                                              

  Software,\         Fiji                                          [@bib47] (Fiji.sc)                                                RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                        
  algorithm                                                                                                                                                                                                              

  Software,\         ImageLab                                      BioRad                                                                                                                                                
  algorithm                                                                                                                                                                                                              

  Other              Probe: *Ctgf*                                 ACDBio                                                            Cat\# 314541                                                                        

  Other              Probe: *Cyr61*                                ACDBio                                                            Cat\# 429001                                                                        

  Other              Probe: *Lats2*                                ACDBio                                                            Cat\# 420271                                                                        

  Other              Probe: *Nr5a1*                                ACDBio                                                            Cat\# 445731                                                                        

  Other              Probe: *Tbx19*                                ACDBio                                                            Cat\# 484741                                                                        

  Other              Probe: *Pou1f1*                               ACDBio                                                            Cat\# 486441                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Animal husbandry was carried out under compliance of the Animals (Scientific Procedures) Act 1986, Home Office license and KCL ethical review approval.

The *Hesx1^Cre/+^* [@bib2]*, Sox2^CreERT2/+^* [@bib4], *Yap^fl/fl^* ^25^, *Taz^-/-^* [@bib52] (JAX:011120), *R26^mTmG/+^* [@bib34] (JAX:007576), *ROSA26^rtTA/+^* [@bib56] (JAX:016999), *Col1a1^tetO-Yap/+^* [@bib20] (MGI:5430522), *Stk3^fl/fl^; Stk4^fl/fl^* [@bib29] (JAX:017635), and *Lats1^fl/fl^* [@bib16] (JAX:024941) and *Lats2^fl/fl^* [@bib16] (JAX:025428) have been previously described.

Tamoxifen (Sigma, T5648) was administered to experimental mice by intraperitoneal injection at a single dose of 0.15 mg/g body weight, or two equal doses on sequential days, depending on the experiment. Mice for growth studies were weighed every week. For embryonic studies, timed matings were set up where noon of the day of vaginal plug was designated as 0.5dpc.

For YAP-TetO experiments, crosses between *Hesx1^Cre/+^;R26^+/+^;Col1a1^+/+^* and *Hesx1^+/+^;R26^rtTA/rtTA^;Col1a1^tetO-Yap/\ tetO-Yap^* animals were set up to generate *Hesx1^Cre/+^;R26^rtTA/+^;Col1a1^tetO-Yap/+^* offspring (hereby YAP-TetO) and control littermates, or crosses between *Sox2^CreERT2/+^;R26^mTmG/mTmG^;Col1a1^+/+^* and *Sox2^+/+^; R26^rtTA/rtTA^;Col1a1^tetO-Yap/\ tetO-Yap^* animals were set up to generate *Sox2^CreERT2/+^;R26^rtTA/mTmG^;Col1a1^tetO-Yap/+^* offspring. While treated with the tetracycline analogue doxycycline, YAP-TetO expressed rtTA from the *ROSA26* locus in *Cre*-derived cells, enabling YAP-S127A expression from the *Col1a1* locus. For embryonic studies between 5.5dpc and 15.5dpc (scheme, [Figure 1A](#fig1){ref-type="fig"}), doxycycline (Alfa Aesar, J60579) was administered to pregnant dams in the drinking water at 2 mg/ml, supplemented with 10% sucrose. For postnatal analyses animals were treated with doxycycline or vehicle (DMSO) as described, from the ages specified for individual experiments on the *Hesx1^Cre/+^* driver, or directly following tamoxifen administration for animals on the *Sox2^CreERT2/+^* driver. Both male and female mice and embryos where included in the studies.

Tissue preparation {#s4-2}
------------------

Embryos and adult pituitaries were fixed in 10% neutral buffered formalin (Sigma) overnight at room temperature. The next day, tissue was washed then dehydrated through graded ethanol series and paraffin-embedded. Embryos up to 13.5dpc were sectioned sagittal and all older embryo and postnatal samples were sectioned frontal, at a thickness of 7 µm for immunofluorescence staining, or 4 µm for RNAscope mRNA in situ hybridisation.

RNAscope mRNA in situ hybridisation {#s4-3}
-----------------------------------

Sections were selected for the appropriate axial level, to include Rathke's pouch or pituitary, as described previously ([@bib28]). The RNAscope 2.5 HD Reagent Kit-RED assay (Advanced Cell Diagnostics) was used with specific probes: *Ctgf, Cyr61, Lats2* (all ACDBio).

H and E staining {#s4-4}
----------------

Sections were dewaxed in histoclear and rehydrated through graded ethanol series from 100% to 25% ethanol, then washed in distilled H~2~O. Sections were stained with Haematoxylin QS (Vector \#H3404) for 1 min, and then washed in water. Slides were then stained in eosin in 70% ethanol for 2 min and washed in water. Slides were dried and coverslips were mounted with VectaMount permanent mounting medium (Vector Laboratories H5000).

Immunofluorescence and immunohistochemistry {#s4-5}
-------------------------------------------

Slides were deparaffinised in histoclear and rehydrated through a descending graded ethanol series. Antigen retrieval was performed in citrate retrieval buffer pH6.0, using a Decloaking Chamber NXGEN (Menarini Diagnostics) at 110°C for 3mins. Tyramide Signal Amplification (TSA) was used for staining using antibodies against YAP (1:1000, Cell Signaling \#4912S), pYAP (1:1000, Cell Signaling \#4911S), TAZ (1:1000, Atlas Antibodies \#HPA007415) and SOX2 (1:2000, Abcam ab97959) with EMCN (1:1000, Abcam ab106100) staining as follows: sections were blocked in TNB (0.1M Tris-HCl, pH7.5, 0.15M NaCl, 0.5% Blocking Reagent (Perkin Elmer FP1020)) for 1 hr at room temperature, followed by incubation with primary antibody at 4°C overnight, made up in TNB. Slides were washed three times in TNT (0.1MTris-HCl pH7.5, 0.15M NaCl, 0.05% Tween-20) then incubated with secondary antibodies (biotinylated anti-rabbit (1:350 Abcam ab6720) and anti-Rat Alexa Fluor 555 (1:300, Life Technologies A21434) for 1 hr at room temperature and Hoechst (1:10000, Life Technologies H3570). Slides were washed again then incubated in ABC reagent (ABC kit, Vector Laboratories PK-6100) for 30 mins, followed by incubation with TSA conjugated fluorophore (Perkin Elmer NEL753001KT) for ten minutes. Slides were washed and mounted with VectaMount (Vector Laboratories H1000).

For regular immunofluorescence, sections were blocked in blocking buffer (0.15% glycine, 2 mg/ml BSA, 0.1% Triton-X in PBS), with 10% sheep serum (donkey serum for goat SOX2 antibody) for 1 hr at room temperature, followed by incubation with primary antibody at 4°C overnight, made up in blocking buffer with 1% serum. Primary antibodies used were against SOX2 (1:250, Immune Systems Ltd GT15098), active YAP (1:300, Abcam ab205270), GFP (1:300, Abcam ab13970), Ki-67 (1:300, Abcam ab16667), SOX9 (1:300, Abcam ab185230), PIT1 (1:1000, Gift from S. Rhodes, Indiana University), TPIT (1:1000, Gift from J. Drouin, Montreal), SF1 (1:200, Life Technologies N1665), Gamma H2A.X (1:1000, Abcam ab2893), Vimentin (1:300, Cell Signaling \#5741), Caspase (1:300, Cell Signaling \#9661S). Slides were washed in PBST then incubated with secondary antibodies for 1 hr at room temperature. Appropriate secondary antibodies were incubated in blocking buffer for 1 hr at room temperature (biotinylated anti-rabbit (1:350, Abcam ab6720), biotinylated anti-mouse (1:350, Abcam ab6788), anti-chicken 488 (1:300, Life Technologies A11039), anti-goat 488 (1:300, Abcam ab150133). Slides were washed again using PBST and incubated with fluorophore-conjugated Streptavidin (1:500, Life Technologies S21381 or S11223) for 1 hr at room temperature, together with Hoechst (1:10000, Life Technologies H3570). Slides were washed in PBST and mounted with VectaMount (Vector Laboratories, H1000).

Immunohistochemistry for the remaining antigens were undertaken on a Ventana Benchmark Autostainer (Ventana Medical Systems) using the following primary antibodies and antigen retrieval: AE1/AE3 (1:100, Dako M351529), CC1 (36 min, Ventana Medical Systems 950--124); Chromogranin (1:400, Dako M086901), CC1 (36 min, Ventana Medical Systems 950--124); NCAM (1:15, Novocastra NCL-L-CD56-504), CC1 (64 min, Ventana Medical Systems 950--124); NSE (1:1000, Dako M087329), CC1 (36 min, Ventana Medical Systems 950--124); p63 (1:100, A. Menarini Diagnostics), CC1 (64 min, Ventana Medical Systems 950--124) and Synaptophysin (1:2, Dako M731529), CC2 (92 min, Ventana Medical Systems 950--124). Targets were detected and viewed using the ultraView Universal DAB Detection Kit (Ventana Medical Systems, 760--500) according to manufacturer's instructions.

Alcian blue with periodic Acid-Schiff staining (AB/PAS) {#s4-6}
-------------------------------------------------------

Following deparaffinisation and rehydration, sections were taken through distilled water then placed in Alcian Blue solution (1% Alcian Blue (Alfa Aeser J60122) in 3% acetic acid (VWR International 20103)) for 20 min. Sections were then placed in 1% periodic acid (VWR 29460) for 10 min, washed in distilled water and transferred to Schiff's reagent (Thermo Fisher Scientific 88017) for 10 min, followed by washing in distilled water for 5 min. Sections were then routinely dried, cleared and mounted.

Western blotting {#s4-7}
----------------

Dissected anterior pituitaries were flash frozen in liquid nitrogen and stored at −80°C. Frozen pituitaries were each lysed in 30 µl of lysis buffer (5 mM Tris, 150 mM NaCl, 1% protease and phosphatase inhibitor (Abcam ab201119), 5 μM EDTA, 0.1% Triton-X, pH7.6) and sonicated at 40% power, twice for ten cycles of: two seconds on/two seconds off, using a Vibra-Cell Processor (Sonics). Protein concentration was determined using the Pierce BCA protein assay kit (Thermo \#23227) and all samples were diluted to 4 mg/ml in Laemmli buffer (Biorad \#161--0747). Proteins were denatured at 95°C for 5 min. Samples were run on a 10% Mini-PROTEAN TGX polyacrylamide gel (BioRad \#4561033), then transferred using Trans-Blot Turbo transfer machine (BioRad) onto polyvinylidene difluoride membranes (BioRad \#1704156). Membranes were blocked with 5% non-fat dairy milk (NFDM) in TBST (20 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH7.6), cut, then incubated with primary antibodies overnight at 4°C as follows: anti-STK3/STK4 (1:5000, Bethyl Laboratories \#A300-466A) or Cyclophilin B (1:1000, R and D Systems \#MAB5410) in 5%NFDM. The next day, membranes were washed in TBST, incubated with secondary antibodies HRP-conjugated anti-Rabbit (1:2000, Cell Signaling \#7074) or HRP-conjugated anti-Mouse (1:2000, Cell Signaling \#7076) in 5% NFDM for 1 hr at room temperature. After washing in TBST, membranes were treated with Clarity Western ECL substrate (Biorad \#170--5060) and bands visualised using the ChemiDoc Touch Imaging System (BioRad). Protein abundance was analysed using ImageLabs (BioRad).

Imaging {#s4-8}
-------

Wholemount images were taken with a MZ10 F Stereomicroscope (Leica Microsystems), using a DFC3000 G camera (Leica Microsystems). For bright field images, stained slides were scanned with Nanozoomer-XR Digital slide scanner (Hamamatsu) and images processed using Nanozoomer Digital Pathology View. Fluorescent staining was imaged with a TCS SP5 confocal microscope (Leica Microsystems) and images processed using Fiji ([@bib47]).

Quantifications and statistics {#s4-9}
------------------------------

Cell counts were performed manually using Fiji cell counter plug-in; 5--10 fields were counted per sample, totalling over 1500 nuclei, across 3--7 pituitaries. Statistical analyses and graphs were generated in GraphPad Prism (GraphPad Software) and the following tests were performed to determine significance: Student's *t*-tests between controls and mutants for [Figures 1D](#fig1){ref-type="fig"} and [2D](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2D and 2E](#fig1s2){ref-type="fig"} (n = 3 of each genotype), [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} (n = 4 of each genotype) and [Figure 5C](#fig5){ref-type="fig"} (n = 4--5 of each genotype); unpaired *t*-test for [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"} (n = 3 per genotype) and [Figure 2---figure supplement 2F](#fig2s2){ref-type="fig"} (n = 6 sections across two samples per genotype); two-tailed *t*-test for [Figure 3C](#fig3){ref-type="fig"} (n = 3 controls, seven mutants); two-way ANOVA with Sidak's multiple-comparison test for [Figure 5F](#fig5){ref-type="fig"} (n = 4--5 of each genotype). For quantification of target expression by RNAscope mRNA in situ hybridisation ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), the area of positive staining (red fluorescence) from 4 μm sections was determined from images using thresholding in Fiji, and quantified as a percentage of total pituitary area in the same image. For statistical testing, one-way ANOVAs with Tukey's multiple comparisons were performed (n = 4 mutants per genotype). Error bars in graphs show ±standard error of the mean, unless otherwise indicated. Quantification of STK3/4 by western blot was carried out on two control (*Stk3^fl/fl^;Stk4^fl/fl^*) and three mutant (*Hesx1^Cre/+^;Stk3^fl/fl^; Stk4^fl/fl^*) samples. A Student's t-test was carried out on normalised band intensities. Chi-squared tests were used to determine significant deviations of observed from expected genotypes presented as tables in [Supplementary files 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}.
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###### Table showing expected and observed frequency of genotypes from *Hesx1^Cre/+^;Yap^fl/fl^;Taz^+/- ^*x *Yap^fl/fl^;Taz^+/- ^*at embryonic 15.5dpc and postnatal day 0--2.

Embryonic: p=0.3471, Chi-square test (two tailed). Postnatal: p=0.0003 (\*\*\*), Chi-square test (two tailed).

10.7554/eLife.43996.017

###### Table showing expected and observed frequency of genotypes from *Hesx1^Cre/+^;Lats1^fl/+^;Lats2^fl/+^* x *Lats1^fl/fl^;Lats2^fl/fl^* and *Hesx1^Cre/+^;Lats1^fl/+^;Lats2^fl/+^* x *Lats1^fl/fl^;Lats2^fl/+^* at embryonic 15.5dpc and postnatal day 0--2.

Embryonic: p\<0.0001 (\*\*\*\*), Chi-square test (two tailed). Postnatal: p\<0.0001 (\*\*\*\*), Chi-square test (two tailed).

10.7554/eLife.43996.018

Data availability {#s7}
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According to UK research councils' Common Principles on Data Policy, all data generated or analysed during this study are included in the manuscript and supporting files.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Homeostatic and tumourigenic activity of *Sox2Sox2*^+^ pituitary stem cells is controlled by the LATS/YAP/TAZ cascade\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Sally A Camper (Reviewer \#1); Elaine Emmerson (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper assesses the roles of key candidates of the hippo pathway (MST, LATS, YAP, and TAZ) in pituitary stem cells (marked by *SOX2*). elegant loss-of-function and gain-of-function in vivo transgenic models coupled with immunofluorescence and high-powered microscopy to demonstrate that deletion of LATS kinases and subsequent upregulation of YAP/TAZ leads to a loss of regulation of SOX2+stem cells and uncontrolled expansion, ultimately leading to the formation of pituitary tumours. This well-written and nicely presented manuscript thoroughly examines the role of the hippo pathway in pituitary development and tumorigenesis. This work will broadly appeal to multiple fields including cancer and stem cell biology and could have significance in understanding the etiology of pediatric pituitary tumors.

Essential revisions:

1\) Subsection "LATS, but not MST, kinases are required for normal pituitary development and differentiation", second paragraph. Since the elimination of *Mst1* and *Mst2* did not produce any phenotype, it is important to demonstrate that the expression of these genes was actually knocked out. The *Hesx1^cre^*strain is reliable and well-characterized, but there are examples of genes that are resistant to being knocked out for unknown reasons. Can you show by PCR or some other method that the genes were knocked out? It is worthwhile adding some discussion about Mst.

2\) Quantification of much of the imaging data would strengthen the manuscript.

Could the authors graphically show the cell quantification data for PIT1, TPIT and SF1 in Figure 1, rather than stating it in the text, as this way the differences and significance would be much easier for the reader to appreciate? Similarly, for Figure 2B; Ki-67, SOX9, Figure 2D; PIT1, TPIT and SF1, Figure 4D; PIT1, TPIT and SF1, and Figure 5I; PIT1/GFP, SF1/GFP and ACTH/GFP.

Did the authors quantify the number of cells expressing SOX2 and active YAP in Figure 1---figure supplement 1D? From the images presented it appears that the number of cells expressing active YAP is reduced in the *Hesx1^Cre/+^; Yap^fl/fl^; Taz*^-/-^ mutants, so quantification would be advantageous.

The authors state an overgrowth of the RP in *Hesx1^Cre/+^; Lats1^fl/fl^; Lats2^fl/fl^* mutants, could they measure and quantify the RP area and present this graphically?

3\) It is not totally convincing that the phenotypic difference of postnatal *Lats1/2* removal (Figure 4) and YAP activation (Figure 5) is due to their intrinsic oncogenic potentials as the authors claim in Figure 6. It is possible that the inability of YAP to drive tumor formation from the Sox2+ stem cells is simply due to the levels of YAP transcriptional output between these two models. The authors should quantitatively measure the expression of YAP/TAZ target genes, such as CTGF, *Cyr61* and ANKRD1.

4\) Are the controls displayed in Figure 3---figure supplement 14F normal tissue from wild-type littermate controls? Would the authors expect them to express markers of adenoma (Synaptophysin, NSE, Chromogranin) so strongly?

5\) It is not clear why the authors restrict the analysis to embryonic stage in *Hesx1^CreER^;R26^rtTA^;YAP^teto^* mice after Dox induction at e5.5. Are they embryonic lethal? If not, what are the postnatal phenotypes in these animals?

10.7554/eLife.43996.021

Author response

> Essential revisions:
>
> 1\) Subsection "LATS, but not MST, kinases are required for normal pituitary development and differentiation", second paragraph. Since the elimination of Mst1 and Mst2 did not produce any phenotype, it is important to demonstrate that the expression of these genes was actually knocked out. The Hesx1^cre^ strain is reliable and well-characterized, but there are examples of genes that are resistant to being knocked out for unknown reasons. Can you show by PCR or some other method that the genes were knocked out? It is worthwhile adding some discussion about Mst.

We agree that it is important to show deletion of *Stk3* and *Stk4 (Mst2 and Mst1)*. To this end we have carried out western blotting using an antibody recognising total STK3/4 proteins. This revealed over 75% overall decrease in STK3/4 protein in total anterior pituitary lysates from P35 *Hesx1^Cre/+^;Stk3^fl/fl^; Hesx1^Cre/+fl/fl^* mutants compared with controls. The data and quantification are incorporated in Figure 2---figure supplement 1 and presented in the subsection "LATS, but not STK, kinases are required for normal pituitary development and differentiation".

We have expanded discussion about STK in the second paragraph of the Discussion.

> 2\) Quantification of much of the imaging data would strengthen the manuscript.
>
> Could the authors graphically show the cell quantification data for PIT1, TPIT and SF1 in Figure 1, rather than stating it in the text, as this way the differences and significance would be much easier for the reader to appreciate? Similarly, for Figure 2B; Ki-67, SOX9, Figure 2D; PIT1, TPIT and SF1, Figure 4D; PIT1, TPIT and SF1, and Figure 5I; PIT1/GFP, SF1/GFP and ACTH/GFP.

We have quantified the data requested in Figures 1, 2, 4 and 5. These are now presented graphically in panels: Figure 1D (lineage markers), Figure 2D (lineage markers), Figure 5I (lineage/GFP), Figure 5---figure supplement 1A (lineage). Additional data, presented as new Figure 1---figure supplement 1B-G (embryonic YAP-TetO postnatal phenotype, see response to Point 5, below) and Figure 2---figure supplement 2F (Ki-67 and SOX9), have also been quantified and presented graphically.

> Did the authors quantify the number of cells expressing SOX2 and active YAP in Figure 1---figure supplement 1D? From the images presented it appears that the number of cells expressing active YAP is reduced in the Hesx1^Cre/+^; Yap^fl/fl^; Taz^-/-^ mutants, so quantification would be advantageous.

We agree with the reviewers that the number of SOX2+ cells expressing active YAP is reduced in these mutants and are keen to emphasise this point. We have quantified the cells expressing SOX2 and active YAP and present these in Figure 1---figure supplement 2D.

> The authors state an overgrowth of the RP in Hesx1^Cre/+^; Lats1^fl/fl^; Lats2^fl/fl^ mutants, could they measure and quantify the RP area and present this graphically?

As suggested, we have measured the area of the RP in these mutants and presented this graphically in Figure 2---figure supplement 2E.

> 3\) It is not totally convincing that the phenotypic difference of postnatal Lats1/2 removal (Figure 4) and YAP activation (Figure 5) is due to their intrinsic oncogenic potentials as the authors claim in Figure 6. It is possible that the inability of YAP to drive tumor formation from the Sox2+ stem cells is simply due to the levels of YAP transcriptional output between these two models. The authors should quantitatively measure the expression of YAP/TAZ target genes, such as CTGF, Cyr61 and ANKRD1.

Unfortunately we have not been able to generate enough new samples to process for qRT from both of these mutants within the revision period. Therefore we have quantitated RNAscope assays across the tumour regions of several mutants of each genotype, facilitated by the auto-fluorescent properties of Fast Red used in this quantitative assay. As expected, the levels of YAP transcriptional output are lower in the YAP-TetO model compared to the LATS1/2 deletion in the *Sox2CreERT2* model. We have included a graph of the quantitation as Figure 5---figure supplement 1E and have included these findings in the Results.

Conceptually, we agree with the reviewers and did not mean to imply that tumours in the LATS1/2 deletion models are due to the intrinsic oncogenic potential of YAP/TAZ. In fact, we are fascinated by the possibility that the strength and duration of YAP/TAZ signaling are the only factors regulating a switch between normal stem cell expansion and tumourigenesis in this setting. Pragmatically, we interpret that results can be due to: (i) enhanced YAP/TAZ activity compared to the YAP-TetO model, as suggested; (ii) additional target expression unique to an increase in TAZ activation, not activated when YAP activity alone is enhanced; or, (iii) abnormal expression of additional, unidentified target proteins of LATS1 that might have oncogenic functions.

We have discussed the differences in levels of signaling between the models in the Discussion section. We have also amended the model in Figure 6 to highlight the difference in the levels of YAP/TAZ target activation.

> 4\) Are the controls displayed in Figure 3---figure supplememt 1F normal tissue from wild-type littermate controls? Would the authors expect them to express markers of adenoma (Synaptophysin, NSE, Chromogranin) so strongly?

Indeed, the controls are from wild-type littermates. We do expect normal endocrine cells of the pituitary to express these neuroendocrine markers strongly (e.g. Stefaneanu L., et al. (1988) Arch Pathol Lab Med. PMID: 3134875; Van Noorden S., et al. (1984) Neuroendocrinology PMID: 6374489; Wilson B.S. and Lloyd R.V. (1984) Am J Pathol. PMID: 6375394). These markers are not diagnostic for pituitary tumour tissue, but are important for the classification of the tumour subtype, since they indicate the neuroendocrine nature of the tumour cells. All adenomas would be positive for Synaptophysin/NSE/Chromogranin, even null-cell adenomas that do not express lineage-commitment transcription factors. The negativity of the tissue is in line with the uncommitted/SOX2+ composition of the tumour, which is not undergoing neuroendocrine commitment as seen in the normal pituitary.

We have clarified that these three are neuroendocrine markers and not markers of adenomas, but that they stain pituitary adenomas, in the last paragraph of the subsection "Loss of LATS kinases results in carcinoma-like murine tumours" (Results).

> 5\) It is not clear why the authors restrict the analysis to embryonic stage in Hesx1^CreER^;R26^rtTA^;YAP^teto^ mice after Dox induction at e5.5. Are they embryonic lethal? If not, what are the postnatal phenotypes in these animals?

We particularly thank the reviewers for this suggestion, as it has revealed a novel phenotype.

Unfortunately with the induction at 5.5dpc, we could not recover any mutants after birth, and have now stated so in the text. However, we adapted the treatment to initiate doxycycline from 9.5dpc and obtained surviving mutants by P24 (4/5). The mutant animals had lower body weight and the anterior pituitary was smaller. Histological examination revealed a phenotype resembling Rathke's cleft cyst, with multiple cysts developing across all mutant pituitaries. These most likely result from an expansion of SOX2+ cells that maintain epithelial integrity, and although we observe postnatal cell lineage commitment, this is impaired, resulting in in a decrease in PIT1+ cells.

Taking our embryonic and postnatal data together, we therefore conclude that a moderate increase in YAP/TAZ target expression maintains and promotes the SOX2+ fate, translating into deregulated lineage commitment and epithelial expansion with variable phenotypes depending on the timing, while a further elevation leads to the uncontrollable expansion and tumourigenesis. The new data are presented as new Figure1---figure supplement 1B-G, (Results subsection "Sustained conditional expression of YAP during development promotes SOX2+ PSC fate") and (Discussion).
